Physician profile
Robert M Wheatley
NPI 1558461970
$4,292.61
in general payments reported to CMS, 2019-2025
26 companies · $81.23 in 2025
The $81.23 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,275 · 2020: $369 · 2021: $646 · 2022: $1,062 · 2023: $709 · 2024: $150 · 2025: $81.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,325.77 | 2019-2023 | Repatha |
| Pfizer INC. | $787.95 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $441.97 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $211.36 | 2020-2022 | |
| Abbott Laboratories | $197.20 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Amarin Pharma, INC. | $192.15 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $162.57 | 2019-2023 | Eliquis |
| Sanofi-Aventis U.S. LLC | $124.75 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $121.33 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $119.88 | 2022 | |
| Esperion Therapeutics, INC. | $104.31 | 2020-2022 | |
| Boston Scientific Corporation | $87.62 | 2022-2023 | Watchman Access System |
| Kowa Pharmaceuticals America, INC. | $69.55 | 2021 | |
| Novo Nordisk INC | $66.50 | 2023 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $40.97 | 2022-2024 | Wainua |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cmp Pharma, INC. | $39.93 | 2022 | |
| Daiichi Sankyo INC. | $38.38 | 2023-2024 | Injectafer |
| Chiesi USA, INC. | $33.15 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.42 | 2019-2022 | |
| Inspire Medical Systems, INC. | $22.77 | 2023 | Inspire |
| Amryt Pharma Holdings LTD | $20.24 | 2021 | |
| Philips North America LLC | $17.11 | 2025 | Mcot |
| Genzyme Corporation | $12.74 | 2022 | |
| Merck Sharp & Dohme LLC | $12.08 | 2021 | |
| Lundbeck LLC | $11.91 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wheatley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.